Abstract
The best known example of an interaction between the liver and the brain is hepatic encephalopathy. In the 90s a central nervous system origin of the pruritis of cholestatic liver disease and more recently of fatigue of liver disease has been suggested. Hence, three important manifestations of liver disease may be of central origin. Evidence is accumulating that the central opioid system is involved in the development of these manifestations. This short review summarizes current knowledge on the role of the opioid system in development of these liver disease manifestations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Basile, A.S., Jones, E.A., and Skolnick, P. (1991). The pathogenesis and treatment of hepatic encephalopathy: Evidence for the involvement of benzodiazepine receptor ligands. Pharm. Rev. 43:27–71.
Bergasa, N.V., Alling, D.W., Talbot, T.L., Swain, M.G., Yurdaydin, C., Turner, M.L., Schmitt, J.M., Walker, E.C., and Jones, E.A. (1995). Effects of naloxone infusions in patients with the pruritis of cholestasis: A double-blind, randomized, controlled trial. Ann. Intern. Med. 123:161–167.
Bergasa, N.V., Alling, D.W., Vergalla, J., and Jones, E.A. (1994). Cholestasis in the male rat is associated with naloxone-reversible antinociception. J. Hepatol. 20:85–90.
Bergasa, N.V., Thomas, D.A., Vergalla, J., Turner, M.L., and Jones, E.A. (1993). Plasma from patients with the pruritis of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci. 53:1253–1257.
Bernstein, J.E., and Swift, R. (1979). Relief of intractable pruritis with naloxone. Arch. Dermatol. 115:1366–1367.
Blum, K., Futtermann, S., Wallace, J.E., and Schwertner, H.A. (1977). Naloxone-induced inhibition of ethanol dependence in mice. Natur 265:49–51.
Butterworth, R.F. (1997). Hepatic encephalopathy: Disorder of multiple neurotransmitter systems. In (C. Record and H. Al-Mardini, eds.) Advances in Hepatic Encephalopathy and Metabolism in Liver Disease, Ipswich, Medical Faculty, Newcastle upon Tyne, pp. 167–175.
Çelik, T., Uzbay, I.T., Çinar, K., Bozkaya, H., Uzunalimoglu, Ö., and Yurdaydin, C. (1999). Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists. J. Hepatol. 31:880–886.
De Waele, J.-P., Audet, R.M., Leong, D.K., and Butterworth, R.F. (1996). Portacaval anastomosis induces regionselective alterations of the endogenous opioid system in the rat brain. Hepatology 24:895–901.
Forton, D.M., Fletcher, A., Thomas, H.C., and Taylor-Robinson, S.D. (2000). Does hepatitis C infection affect the brain? A proton magnetic resonance study. In (C. Yurdaydin and H. Bozkaya, eds.) Advances in Hepatic Encephalopathy and Metabolism in Liver Disease, Turkish Gastroenterology Foundation Press, Ankara, pp. 325–329.
Frederickson, R.C.A., and Norris, F.H. (1976). Enkephalin-induced depression of single neurons in brain areas with opiate receptors-antagonism by naloxone. Science 194:440–442.
Froehlich, J.C., Harts, J., Lumeng, L., and Li, T.K. (1990). Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol. Biochem. Behav. 35:385–390.
Fry, J.P., and Zieglgangsberger, W. (1979). Comparison of the effects of GABA and enkephalin on synaptically evoked activity in the rat striatum. Appl. Neurophysiol. 42:54–56.
Hoyer, D., Clarke, D.E., Fozard J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., and Humphrey, P.P. (1994). International Union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46: 158–201.
Jalan, R., Gibson, H., and Lombard, M.G. (1996). Patients with primary biliary cirrhosis have central but no peripheral fatigue. Gu 39(Suppl.): A30.
Jones, E.A. (1995). Fatigue associated with chronic liver disease: A riddle wrapped in a mystery inside an enigma. Hepatolog 22:1606–1608.
Jones, E.A. (1999). Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lance 354:397.
Jones, E.A. (2000). Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterolog 118:431–432.
Jones, E.A., and Bergasa, N.V. (1999). The pruritis of cholestasis. Hepatolog 29:1003–1006.
Jones, E.A., and Yurdaydin, C. (1997). Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatolog 25:492–494.
Kent, S., Bluthe, R.-M., Kelley, K.W., and Dantzer R. (1992). Sickness behavior as a new target for drug development. TIPS 13:24–28.
Laidlaw, J., Read, A.E., and Sherlock, S. (1961). Morphine tolerance in hepatic cirrhosis. Gastroenterolog 40:389–396.
Martin, J.R., Parchet, H., Buhler, R., and Bircher, J. (1985). Increased ethanol consumption and blood ethanol levels in rats with portacaval shunts. Am. J. Physiol. 248:G287–G292.
Metze, D., Reimann, S., Beissert, S., and Luger T. (1999). Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritis in internal and dermatological diseases. J. Am. Acad. Dermatol. 41:533–539.
Millan, M.J., and Herz, A. (1985). The endocrinology of the opioids. Inter. Rev. Neurobiol. 26:1–83.
Murphy, M., and Carmichael, A.J. (2000). Renal itch. Clin. Exp. Dermatol. 25:103–106.
Özsoylu, S., and Koçak, N. (1985). Naloxone in hepatic encephalopathy. Am. J. Dis. Child. 139:749–750.
Sirnes, T.B. (1953). Voluntary ethanol consumption of alcohol in rats with cirrhosis of the liver. Q. J. Study Alcoho 14:3–18.
Swain, M.G., and Maric, M. (1997). Improvement in cholestasis-associated fatigue with a serotonin receptor antagonist using a novel rat model of fatigue assessment. Hepatolog 25:291–294.
Terrault, N.A., and Wright, T.L. (1998). Viral hepatitis A through G. In (M. Feldman, M.H. Sleisinger, and B.F. Scharschmidt, eds.) Gastrointestinal and Liver Disease, 6th edn.; Vol. 2, W.B. Saunders pp. 1123–1170.
Thornton, J.R., and Losowsky, M.S. (1988). Opioid peptides and primary biliary cirrhosis. Br. Med. J. 297:1501–1504.
Thornton, J.R., and Losowsky, M.S. (1989). Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J. Hepatol. 8:53–59.
Wilson, W.M., and Maughan, R.J. (1992). Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: Administration of paroxetine, a 5-HT reuptake inhibitor, reduces the capacity to perform prolonged exercise. Exp. Physiol. 77:921–924.
Wolfhagen, F.H., Sternieri, E., Hop, W.C., Vitale, G., Bertolett, M., and van Buuren, H.R. (1997) Oral naltrexone treatment for choestatic pruritis: a double-blind, placebo-controlled study. Gastroenterolog 113:1264–1269.
Yurdaydin, C., Karavelioglu, D., Onaran, O., Çelik, T., Yasa, M.H., and Uzunalimoglu, Ö. (1998). Opioid receptor ligands in human hepatic encephalopathy. J. Hepatol. 29:796–801.
Yurdaydin, C., Li, Y., Ha, Y.-H., Jones, E.A., Rothman, R., and Basile, A.S. (1995). Brain and plasma levels of opioid peptides and altered in rats with thioacetamide-induced fulminant hepatic failure: Implications for the treatment of hepatic encephalopathy with opioid antagonists. J. Pharmacol. Exp. Ther. 273:185–192.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yurdaydin, C. The Central Opioid System in Liver Disease and Its Complications. Metab Brain Dis 16, 79–83 (2001). https://doi.org/10.1023/A:1011618729660
Issue Date:
DOI: https://doi.org/10.1023/A:1011618729660